Inhibition of PTGS2 decreases tumor multiplicity in numerous murine models and, according to many randomized controlled clinical trials, prevents CRC (Fischer et al., 2011; Janakiram and Rao, 2014; Katona and Weiss, 2020). Here, PTGS2 is linked to colorectal carcinoma.